Brought to you by 
BMS buys start-up IFM for $300mm up front plus over $2bn in earn-outs
04 Sep 2020
Executive Summary
Bristol-Myers Squibb Co. paid $300mm up front for IFM Therapeutics, a private start-up aiming to treat diseases by targeting the innate immune system.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com